NewslettersMammary Cell NewsAnti-Tumor Activity and Biomarker Analysis for TROP2-Antibody Drug Conjugate Datopotamab Deruxtecan in Patient-Derived Breast Cancer Xenograft ModelsBy Jamie Kang - November 27, 2024023Scientists tested the activity of datopotamab deruxtecan in a panel of breast cancer patient-derived xenografts varying in TROP2 expression.[Clinical Cancer Research]Abstract